02/11
Headlines

REGN

Why Making Dramatic Moves : GrubHub Inc. (NYSE:GRUB), Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), Taylor Devices Inc. (NASDAQ:TAYD), AMN Healthcare Services Inc. (NYSE:AHS), REGN

Adam Keintzel03 mins

Matt Maloney, the co-founder and CEO of Chicago-based GrubHub Inc. (NYSE:GRUB) Seamless, and his wife paid $3.44 million this month for a six-bedroom, 7,000-square-foot vintage mansion in Lincoln Park. GrubHub Inc. (NYSE:GRUB) belongs to Technology sector. Its net profit margin is 4.80% and weekly performance is 0.51%. On last trading day company shares ended up…

Read More

Stocks in Focus : AK Steel Holding (NYSE:AKS), Regeneron Pharmaceuticals (NASDAQ:REGN), Kayne Anderson Energy Development (NYSE:KED), Penn Virginia (NYSE:PVA), China Information (NASDAQ:CNIT)

Jayne Crisman03 mins

Shares of AK Steel Holding (NYSE:AKS) have been given a consensus recommendation of “Hold” by the ten ratings firms that are covering the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating on the company.  AK Steel Holding Corporation…

Read More

Stocks to Watch on Monday: Regeneron Pharmaceuticals (NASDAQ:REGN), Symantec Corporation (NASDAQ:SYMC), Hewlett-Packard (NYSE:HPQ), First Solar (NASDAQ:FSLR)

Jayne Crisman02 mins

Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) and Novartis (NYSE: NVS ) enjoy little competition for their vision-improving drugs Eylea and Lucentis. As a result, sales of Eylea grew to more than $1.8 billion last year, just two years after winning FDA approval in 2011, and sales of Novartis and Roche’s (NASDAQOTH: RHHBY ) Lucentis, which…

Read More

Stocks Moving After-Hours: Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Kinder Morgan Management (NYSE:KMR), FutureFuel (NYSE:FF)

Mark DeFrance02 mins

Citigroup upgraded it rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company’s Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron’s pipeline is not adequately reflected in the current share price. The firm raised its price target for the…

Read More

BioTech After Hours Active Stocks: Regeneron (NASDAQ:REGN), Ambarella (NASDAQ:AMBA), Progress Software (NASDAQ:PRGS)

Mark Doerr03 mins

In a note issued Friday, Piper Jaffray said the weakness in Regeneron (NASDAQ:REGN) is a buying opportunity, as the firm sees risks to the company’s alirocumab Phase III program as overblown, with neither Regeneron  (NASDAQ:REGN) or its development partner Sanofi (SNY) having seen any neurocognitive adverse events with the drug. The firm reiterates a Buy rating…

Read More